Spruce Biosciences (SPRB) Reiterated at Market Outperform by Citizens on TA-ERT Therapy Lead

September 24, 2026 4:19 AM

Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $144.00 price target on Spruce Biosciences, Inc. (NASDAQ: SPRB).The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found